BenevolentAI's founder, Kenneth Mulvany, plans to nominate new directors to improve governance and accountability amid a 90% share price decline.
BenevolentAI's founder and largest shareholder, Kenneth Mulvany, intends to nominate new directors and potentially remove existing ones to improve governance and accountability within the company, which has seen its share price decline by over 90%. Mulvany aims to elevate patient care through relentless innovation and sustained growth, with the support of shareholders at the Annual General Meeting. This move follows significant achievements in drug discovery and development.
April 02, 2024
3 Articles